Navigation Links
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
Date:7/2/2009

PALATINE, Ill. and BRISTOL, Tenn., July 2 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug Application (NDA) for Acurox (oxycodone HC1, USP and niacin, USP) Tablets CII, an immediate release product intended for the relief of moderate-to-severe pain.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090702/DC41417LOGO-a )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090702/DC41417LOGO-b )

The Complete Response Letter raises issues regarding the potential abuse deterrent benefits of Acurox(R). Acura and King are currently evaluating the FDA's Complete Response Letter, and at this stage believe they can respond to the issues raised without conducting any additional studies. The Companies plan to meet with the FDA following submission of their response.

About Acurox Tablets

Acurox is a patented, orally administered, immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient with a proposed indication for the relief of moderate-to-severe pain. Acurox utilizes Acura's proprietary Aversion Technology, which is designed to deter misuse and abuse by intentional swallowing of excess quantities of tablets, intravenous injection of di
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
2. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
3. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
5. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
6. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
7. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
10. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
11. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Apr. 16, 2015 Research and Markets ... "Corporate Reputation of Pharma in 2014 - a ... report to their offering. For the ... on the corporate reputation of the pharmaceutical industry held ... with the views of patient organisations representing all therapy ...
(Date:4/16/2015)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... commercialization of products for the treatment of central nervous ... the first quarter of 2015 on Wednesday, May 6, ... Company will host a conference call at 4:30 PM ... management will discuss the first quarter 2015 financial results ...
(Date:4/16/2015)...  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) will report ... Wednesday, May 6, 2015, following the close of the U.S. ... call and live webcast on the same day at 5:00 ... the financial results.  To access the webcast ... "Investors" link.  Please log onto the webcast prior to the ...
Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3
... 2011 Unilife Corporation ("Unilife" or the "Company") (Nasdaq: ... be presenting at Cowen and Company,s 31st Annual Health Care ... Boston. Alan Shortall, Chief Executive Officer of Unilife, is scheduled ... 2011. The conference presentation will be broadcast over ...
... VICTOR, N.Y., March 7, 2011 PharmaNova, Inc. ... whereby Lacerta Bio,s experienced team of business development ... and U.K. to support its 2011 business growth ... PharmaNova,s partnering base for its innovative, nanoparticle technology, ...
Cached Medicine Technology:Unilife to Present at the 31st Annual Cowen Health Care Conference on Wednesday, March 9, 2011 in Boston 2PharmaNova Fuels Business Growth with Lacerta Bio Partnership 2
(Date:4/17/2015)... From the day Dr. Todd Phillips founded The Last ... empowered young people to create meaningful change in their world. ... and the Gospel to all of Liberia by 2020 , ... 27, students, faculty and staff raised $21,000 through the TEN ... the Good News of Jesus. , During the campaign, ...
(Date:4/17/2015)... Representatives Jim Himes (D-CT) and Ed Royce ... 1849 in congress on April 16, 2015 in an ... with the genetic disease. , The bill, similar ... first to create a federally led and financed initiative ... telangiectasia. This would effectively prevent premature death and disability ...
(Date:4/17/2015)... Hollywood, California (PRWEB) April 17, 2015 ... Durkin Entertainment’s EcoLuxe Lounge and the “Salute to the ... the luxurious Beverly Hilton Hotel, overlooking the impressive Los ... nominees were organized by Debbie Durkin, LA’s leading producer ... , Showcasing many of the world’s premier providers of ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Baptist Health ... have signed a partnership agreement designed to transform oncology ... The institutions have agreed to create a joint cancer ... protocols and translational research. Baptist MD Anderson Cancer Center ... providing a single destination for highly coordinated, multidisciplinary cancer ...
(Date:4/17/2015)... 2015 The American College of Traditional Chinese Medicine ... Day on April 29. The event will be held from 11 ... 555 DeHaro St. in San Francisco, CA. , The agenda for ... at the DeHaro campus (room F), 11:10 a.m. – Introduction ... – Light lunch with current students, faculty and staff, 1 p.m. ...
Breaking Medicine News(10 mins):Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:American College of Traditional Chinese Medicine Hosts Open House 2
... For patients with,rheumatoid arthritis, combining one well-known, lower ... works best to reduce joint,swelling or tenderness, according to ... and Quality, part of the U.S. Department of Health ... be posted on-line,Monday in the Annals of Internal Medicine., ...
... Minn., Nov. 19 Regions Hospital today was,named one ... care based on the Cardiovascular Benchmarks for Success,Study by ... 100 hospital comes as a result of the hard ... with the,excellent care provided to patients and an investment ...
... guide development, scientists say , MONDAY, Nov. 19 (HealthDay News) ... embryonic cells regulate levels of retinoic acid, a derivative of ... embryo development, acting as a signal between cells to control ... embryos that get too much or too little retinoic acid ...
... 19 Smith & Nephew,s,(NYSE: SNN ) (LSE: ... business to InaVein LLC, a Boston-area investor group led ... medical,device marketplace. Terms of the sale were not disclosed. ... product portfolio,as part of Smith & Nephew,s overall Earnings ...
... OMCL ) a leading provider of systems and ... today announced that Randall A. Lipps, chairman, president &,CEO ... at the Piper Jaffray,19th Annual Health Care Conference at ... scheduled to begin at 12:00 p.m. on Wednesday,November 28, ...
... different than men,s way beyond their reproductive systems. Women wake ... and are more likely to suffer from depression and sleep ... , Yet, there,s a cavernous void in research based ... on men and the findings applied to women. , ...
Cached Medicine News:Health News:Combining Medications Often Best Strategy to Battle Rheumatoid Arthritis 2Health News:Combining Medications Often Best Strategy to Battle Rheumatoid Arthritis 3Health News:Research Reveals Nutrient's Impact on the Embryo 2Health News:Smith & Nephew Endoscopy Announces the Sale of its Vascular Business 2Health News:Smith & Nephew Endoscopy Announces the Sale of its Vascular Business 3Health News:Omnicell to Present at Piper Jaffray 19th Annual Health Care Conference 2Health News:Women aren't men 2Health News:Women aren't men 3
The RU is a low profile implantable bipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model)....
The Petite leads are low profile (4.8F lead body diameter) implantable endocardial pacing leads which are manufactured using a new proprietary hexafilar coil for permanent stimulation of the ventricl...
The Vitatron Excellence S+ lead series are endocardial leads providing excellent reliability and optimal pacing characteristics....
... Impulse II lead series are silicon ... extend the longevity of the pacemaker ... The high impedance of the lead ... electrode surface, combined with the elution ...
Medicine Products: